Bedrijfstakpensioenfonds Voor DE Media PNO lowered its stake in Eli Lilly and Company (NYSE:LLY) by 35.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,658 shares of the company’s stock after selling 75,442 shares during the period. Eli Lilly and makes up about 1.3% of Bedrijfstakpensioenfonds Voor DE Media PNO’s portfolio, making the stock its 27th largest position. Bedrijfstakpensioenfonds Voor DE Media PNO’s holdings in Eli Lilly and were worth $11,247,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. BlackRock Inc. increased its stake in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares during the period. Beutel Goodman & Co Ltd. acquired a new stake in Eli Lilly and during the first quarter worth about $161,084,000. Vanguard Group Inc. increased its stake in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares during the period. Winslow Capital Management LLC increased its stake in Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock worth $326,008,000 after buying an additional 1,719,538 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after buying an additional 1,441,200 shares during the period. Institutional investors and hedge funds own 75.61% of the company’s stock.
Eli Lilly and Company (NYSE LLY) opened at 81.97 on Wednesday. The company has a market capitalization of $86.48 billion, a PE ratio of 35.47 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The company’s 50-day moving average price is $83.03 and its 200 day moving average price is $81.54.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 earnings per share. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.54%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio is 90.04%.
ILLEGAL ACTIVITY NOTICE: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/eli-lilly-and-company-nyselly-shares-sold-by-bedrijfstakpensioenfonds-voor-de-media-pno-updated/1313126.html.
A number of analysts recently issued reports on LLY shares. UBS AG downgraded shares of Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. Piper Jaffray Companies reissued a “buy” rating and set a $100.00 target price on shares of Eli Lilly and in a research report on Monday, April 17th. Argus downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating and increased their target price for the stock from $64.18 to $81.00 in a research report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC reissued a “buy” rating and set a $93.00 target price on shares of Eli Lilly and in a research report on Thursday, June 22nd. Finally, Sanford C. Bernstein reissued an “outperform” rating and set a $88.00 target price on shares of Eli Lilly and in a research report on Sunday, May 21st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $88.27.
In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total value of $17,855,750.00. Following the sale, the insider now owns 124,475,804 shares of the company’s stock, valued at approximately $10,337,715,522.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the sale, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 669,733 shares of company stock worth $55,845,287. 0.20% of the stock is owned by insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.